Corvus Pharmaceuticals CRVS
NASDAQ CRVS
$14.39 -0.26 (-1.77%)
As of: Sep 4, 2026 · 3:59 PM EDT

Corvus Pharmaceuticals (CRVS) Profit After Tax Growth (5y) (2020 - 2026)

Analysis

Corvus Pharmaceuticals (CRVS) Profit After Tax Growth (5y) (2020 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Corvus Pharmaceuticals 1.33 Bn 1.12 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -9.05%
Mar 31, 2026 -3.41%
Sep 30, 2025 -0.73%
Jun 30, 2025 5.50%
Mar 31, 2025 25.99%
Sep 30, 2024 -29.59%
Jun 30, 2024 19.96%
Mar 31, 2024 13.31%
Dec 31, 2023 10.08%
Sep 30, 2023 10.36%
Jun 30, 2023 10.98%
Mar 31, 2023 11.25%
Dec 31, 2022 5.09%
Sep 30, 2022 -5.17%
Jun 30, 2022 11.01%
Mar 31, 2022 12.35%
Dec 31, 2021 3.59%
Sep 30, 2021 -0.74%
Jun 30, 2021 -6.33%
Mar 31, 2021 -12.78%